Prognostic Value of MicroRNAs in Patients after Myocardial
Infarction: A Substudy of PRAGUE-18

J 2019

Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18

HROMADKA, M., V. CERNA, M. PESTA, A. KUCEROVA, Jiří JARKOVSKÝ et. al.

Basic information

Original name

Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18

Authors

HROMADKA, M. (203 Czech Republic), V. CERNA (203 Czech Republic, guarantor), M. PESTA (203 Czech Republic), A. KUCEROVA (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), D. RAJDL (203 Czech Republic), R. ROKYTA (203 Czech Republic) and Z. MOTOVSKA (203 Czech Republic)

Edition

Disease Markers, London, Hindawi Publishing Corporation, 2019, 0278-0240

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.738

RIV identification code

RIV/00216224:14110/19:00112608

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1155/2019/2925019

UT WoS

000498386400001

Keywords in English

SUDDEN CARDIAC DEATH; CIRCULATING MICRORNAS; NATRIURETIC PEPTIDE; RISK STRATIFICATION; PREDICTORS; PRASUGREL; MORTALITY; OUTCOMES; IMPACT; DAMAGE

Abstract

V originále

Background. The evaluation of the long-term risk of major adverse cardiovascular events and cardiac death in patients after acute myocardial infarction (AMI) is an established clinical process. Laboratory markers may significantly help with the risk stratification of these patients. Our objective was to find the relation of selected microRNAs to the standard markers of AMI and determine if these microRNAs can be used to identify patients at increased risk. Methods. Selected microRNAs (miR-1, miR-133a, and miR-499) were measured in a cohort of 122 patients from the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI treated with primary percutaneous coronary intervention (pPCI)). The cohort was split into two subgroups: 116 patients who did not die (survivors) and 6 patients who died (nonsurvivors) during the 365-day period after AMI. Plasma levels of selected circulating miRNAs were then assessed in combination with high-sensitivity cardiac troponin T (hsTnT) and N-terminal probrain natriuretic peptide (NT-proBNP). Results. miR-1, miR-133a, and miR-499 correlated positively with NT-proBNP and hsTnT 24 hours after admission and negatively with left ventricular ejection fraction (LVEF). Both miR-1 and miR-133a positively correlated with hsTnT at admission. Median relative levels of all selected miRNAs were higher in the subgroup of nonsurvivors (N=6) in comparison with survivors (N=116), but the difference did not reach statistical significance. All patients in the nonsurvivor subgroup had miR-499 and NT-proBNP levels above the cut-off values (891.5 ng/L for NT-proBNP and 0.088 for miR-499), whereas in the survivor subgroup, only 28.4% of patients were above the cut-off values (p=0.001). Conclusions. Statistically significant correlation was found between miR-1, miR-133a, and miR-499 and hsTnT, NT-proBNP, and LVEF. In addition, this analysis suggests that plasma levels of circulating miR-499 could contribute to the identification of patients at increased risk of death during the first year after AMI, especially when combined with NT-proBNP levels.

Citovat

HROMADKA, M., V. CERNA, M. PESTA, A. KUCEROVA, Jiří JARKOVSKÝ, D. RAJDL, R. ROKYTA and Z. MOTOVSKA. Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18. Disease Markers. London: Hindawi Publishing Corporation, 2019, vol. 2019, NOV 3 2019, p. 1-9. ISSN 0278-0240. Available from: https://dx.doi.org/10.1155/2019/2925019.

@article{1606901,
   author = {Hromadka, M. and Cerna, V. and Pesta, M. and Kucerova, A. and Jarkovský, Jiří and Rajdl, D. and Rokyta, R. and Motovska, Z.},
   article_location = {London},
   article_number = {NOV 3 2019},
   doi = {http://dx.doi.org/10.1155/2019/2925019},
   keywords = {SUDDEN CARDIAC DEATH; CIRCULATING MICRORNAS; NATRIURETIC PEPTIDE; RISK STRATIFICATION; PREDICTORS; PRASUGREL; MORTALITY; OUTCOMES; IMPACT; DAMAGE},
   language = {eng},
   issn = {0278-0240},
   journal = {Disease Markers},
   title = {Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18},
   url = {http://dx.doi.org/10.1155/2019/2925019},
   volume = {2019},
   year = {2019}
}

TY  - JOUR
ID  - 1606901
AU  - Hromadka, M. - Cerna, V. - Pesta, M. - Kucerova, A. - Jarkovský, Jiří - Rajdl, D. - Rokyta, R. - Motovska, Z.
PY  - 2019
TI  - Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18
JF  - Disease Markers
VL  - 2019
IS  - NOV 3 2019
SP  - 1-9
EP  - 1-9
PB  - Hindawi Publishing Corporation
SN  - 02780240
KW  - SUDDEN CARDIAC DEATH
KW  - CIRCULATING MICRORNAS
KW  - NATRIURETIC PEPTIDE
KW  - RISK STRATIFICATION
KW  - PREDICTORS
KW  - PRASUGREL
KW  - MORTALITY
KW  - OUTCOMES
KW  - IMPACT
KW  - DAMAGE
UR  - http://dx.doi.org/10.1155/2019/2925019
L2  - http://dx.doi.org/10.1155/2019/2925019
N2  - Background. The evaluation of the long-term risk of major adverse cardiovascular events and cardiac death in patients after acute myocardial infarction (AMI) is an established clinical process. Laboratory markers may significantly help with the risk stratification of these patients. Our objective was to find the relation of selected microRNAs to the standard markers of AMI and determine if these microRNAs can be used to identify patients at increased risk. Methods. Selected microRNAs (miR-1, miR-133a, and miR-499) were measured in a cohort of 122 patients from the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI treated with primary percutaneous coronary intervention (pPCI)). The cohort was split into two subgroups: 116 patients who did not die (survivors) and 6 patients who died (nonsurvivors) during the 365-day period after AMI. Plasma levels of selected circulating miRNAs were then assessed in combination with high-sensitivity cardiac troponin T (hsTnT) and N-terminal probrain natriuretic peptide (NT-proBNP). Results. miR-1, miR-133a, and miR-499 correlated positively with NT-proBNP and hsTnT 24 hours after admission and negatively with left ventricular ejection fraction (LVEF). Both miR-1 and miR-133a positively correlated with hsTnT at admission. Median relative levels of all selected miRNAs were higher in the subgroup of nonsurvivors (N=6) in comparison with survivors (N=116), but the difference did not reach statistical significance. All patients in the nonsurvivor subgroup had miR-499 and NT-proBNP levels above the cut-off values (891.5 ng/L for NT-proBNP and 0.088 for miR-499), whereas in the survivor subgroup, only 28.4% of patients were above the cut-off values (p=0.001). Conclusions. Statistically significant correlation was found between miR-1, miR-133a, and miR-499 and hsTnT, NT-proBNP, and LVEF. In addition, this analysis suggests that plasma levels of circulating miR-499 could contribute to the identification of patients at increased risk of death during the first year after AMI, especially when combined with NT-proBNP levels.
ER  -

HROMADKA, M., V. CERNA, M. PESTA, A. KUCEROVA, Jiří JARKOVSKÝ, D. RAJDL, R. ROKYTA and Z. MOTOVSKA. Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18. \textit{Disease Markers}. London: Hindawi Publishing Corporation, 2019, vol.~2019, NOV 3 2019, p.~1-9. ISSN~0278-0240. Available from: https://dx.doi.org/10.1155/2019/2925019.

Detailed Information on Publication Record